Langzeit-EKG
CAST was a multicenter, double-blind, randomized, controlled trial. Patients were randomized to drug therapy or placebo if they met these criteria: They had a myocardial infarction occurring six days to two years prior to the onset of the study, and they had asymptomatic ventricular premature beats, detected by Holter monitor, which could be suppressed by either encainide, flecainide, or moracizine in an open-label design. A total of 1727 subjects who responded were randomized, 1455 to encainide, flecainide, or placebo, and 272 to moracizine or placebo. The primary endpoint was sudden cardiac death, and the secondary endpoint was all-cause mortality.